<DOC>
	<DOCNO>NCT02228174</DOCNO>
	<brief_summary>The objective study establish safety effectiveness Sonata® System treatment symptomatic uterine fibroid .</brief_summary>
	<brief_title>Sonography Guided Transcervical Ablation Uterine Fibroids</brief_title>
	<detailed_description>In single-arm study , subject symptomatic uterine fibroid transcervical RF ablation uterine fibroid intrauterine ultrasound guidance use Gynesonics Sonata System .</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Menorrhagia</mesh_term>
	<mesh_term>Zaleplon</mesh_term>
	<criteria>premenopausal ≥ 25 ≤ 50 year age time enrollment experience heavy menstrual bleeding associate fibroid ( AUBL ) least 3 month 110 fibroid FIGO type 1 , 2 , 3 , 4 , and/or type 25 , diameter ≥ 1.0 cm ≤ 5.0 cm least one type 1 , type 2 , type 3 , type 25 fibroid . PBAC score ≥ 150 ≤ 500 consistent menstrual cycle material risk pregnancy speak read language validate questionnaire available willing able read , understand , sign inform consent form , participate study adhere study followup requirement pregnancy urgent need surgery treat fibroid symptom desire current future childbearing presence tubal implant sterilization postmenopausal history presence type 0 fibroid , unless &lt; 1 cm diameter presence single polyp ≥ 1.5 cm , multiple polyp size fibroid FIGO type 1 , type 2 , type 3 , type 4 , type 25 diameter &gt; 5.0 cm bulk symptom presence one fibroid FIGO type 5 , type 6 , type 7 exclusive presence fibroid insufficient explain severity symptom presence clinically relevant fibroid treat technical reason presence extrauterine pelvic mass diagnose benign IUD/IUS situ within washout period previous procedure fibroid heavy menstrual bleed myomectomy myomectomy within 12 month abnormality endometrial cavity obstruct access handpiece contraindication MRI total uterine volume &gt; 1000 cc clinically significant adenomyosis confirm suspected diagnosis clinically relevant endometriosis one clinically relevant fibroid significantly calcify . previous pelvic irradiation renal insufficiency [ serum creatinine ≥ 1.5 mg/dL ( 132.6 μmol/L ) ] evidence disorder hemostasis ( AUBC ) abnormal cervical cytology unevaluated untreated adherence national guideline endometrial hyperplasia ( AUBM ) , include simple hyperplasia without atypia confirm abdominal / pelvic malignancy within previous five year active pelvic infection current positive testing pelvic gonorrhea chlamydia ; use hormonallyrelevant medication within washout period use antifibrinolytic agent undergo screen procedure current use anticoagulant therapy chronic pelvic pain ( disruptive least six month ) significant baseline pelvic menstrual pain chronic uncontrolled moderate severe hypertension hypoplastic otherwise short uterus major medical psychiatric illness factor may affect general health subject 's ability adhere followup schedule provide valid subject selfassessment data reason individual study subject appropriate suitable participation</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Abnormal Uterine Bleeding associate fibroid</keyword>
	<keyword>AUB-L</keyword>
	<keyword>Fibroids</keyword>
	<keyword>Heavy menstrual bleeding</keyword>
	<keyword>HMB</keyword>
	<keyword>Myoma</keyword>
	<keyword>Menorrhagia</keyword>
</DOC>